TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05058963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantram repetition program
Description: Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use
Study: NCT05240079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate measurement with Caducy system (twice). SpO2 measurement with Caducy system (Twice).
Description: Heart rate and SpO2 measurement with Caducy (the visage of the subject is filmed 30 seconds and 1 minute with a camera) and heart rate and SpO2 measurement with gold standard (heart rate monitor and oximeter pod linked to an acquisition station). The procedure is repeated twice.
Study: NCT05429905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase I
Description: * Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~* Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~* Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase II
Description: RP2D will be determined in Phase I

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase II
Description: RP2D will be determined in Phase I
Study: NCT05310851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI and non-nutritive sucking
Description: PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI and non-nutritive sucking
Description: PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes.
Study: NCT06315504

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT06273592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based meal
Description: Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based meat meal
Description: Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
Study: NCT05985759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyle cystiene
Description: N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
Study: NCT05512663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Description: The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
Study: NCT05913193

Intervention type: OTHER
Intervention: Oral Nutritional Supplement (ONS)
Description: Diabetes specific oral nutritional supplement
Study: NCT06074029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitors
Description: Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
Study: NCT04839016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05217160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KeraStat® Gel with Morphine application
Description: Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KeraStat® Gel application
Description: Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes.
Study: NCT06194214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered Orally.
Study: NCT04709042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chordal tension measurement
Description: The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (MRI)
Description: Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
Study: NCT04929535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen Peroxide 30 % Topical Solution
Description: Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide 30 % Topical Solution
Description: Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
Study: NCT05832697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid 250 Mg Oral Tablet
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid 250 Mg Oral Tablet
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid 250 Mg Oral Tablet
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
Study: NCT06288048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT
Description: Experimental:~Target: Proximal third of m. Brachioradialis (BR) Patient position: Seated Therapist position: Same side as needle insertion Needle insertion direction: Lateral-to-medial towards clinician\&#39;s finger Needle type: AguPunt® Barcelona, Spain Technique: Seek three local twitch responses in m. Brachioradialis (BR) Alternative for no responses: 10 needle insertions and withdrawals at 1 Hz frequency~Ischemic Compression (IC):~Applied using sphygmomanometer on seated subject\&#39;s arm Pressure: Increased until ischemic pain (approx. 200 mmHg) Duration: Maintained for 90 seconds~Combined with three applications of Cryos Phyto Performance 400 ml cold spray synchronized with m. Brachioradialis (BR) stretching:~Stretching: Passive sustained mobilization with elbow extension and forearm pronation for 10 seconds~Mirror Therapy (MFT):~Setup: Patient seated with forearms resting on bed Mirror: 35 x 35 cm, covering punctured side at 45-degree angle for hand visualization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching
Description: The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject\&#39;s arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
Study: NCT05832697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid 250 Mg Oral Tablet
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
Study: NCT05042492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gekoTM
Description: The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
Study: NCT05565937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BL-3100-NBR03 multi-purpose solution
Description: BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: renu® Advanced Formula multi-purpose solution
Description: renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
Study: NCT05998967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Mantram Repetition Program
Description: Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mantram Repetition Program
Description: Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
Study: NCT06091514

Intervention type: DEVICE
Group type: OTHER
Intervention: CS Medical Watch
Description: The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).

Intervention type: OTHER
Group type: OTHER
Intervention: Specific questionnaire
Description: Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
Study: NCT05413772

Intervention type: OTHER
Intervention: Temocillin
Description: To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections

Intervention type: OTHER
Intervention: Temocillin
Description: To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
Study: NCT05512559

Intervention type: DEVICE
Intervention: body composition analysis
Description: Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
Study: NCT05627687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate Variability Biofeedback
Description: Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music Listening Control
Description: Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
Study: NCT05670015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dosage selective alpha-2 receptor agonists topical eyedrop
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dosage selective alpha-2 receptor agonists topical eyedrop
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dosage selective alpha-2 receptor agonists topical eyedrop
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Study: NCT06486701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: have a sing
Description: Singing
Study: NCT06216496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic test for amino acid metabolism
Description: Subjects are fasting, and the dynamic test is performed as follows:~Placement of 1 peripheral venous line (for infusions).~* H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose)~* H1,5: initial blood sampling (amino acid assay)~* H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose)~* H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate.
Study: NCT05670015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dosage selective alpha-2 receptor agonists topical eyedrop
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Study: NCT06169722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDI01 suspension
Description: 200mg or 400mg oral once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDI01 suspension
Description: 200mg or 400mg oral once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDI01 suspension
Description: 200mg or 400mg oral once a day
Study: NCT06262074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise Program
Description: 30 minutes of structured exercise programs

Intervention type: OTHER
Group type: OTHER
Intervention: Non structured exercise program
Description: Non structured exercises
Study: NCT06231524

Intervention type: OTHER
Intervention: Analyse pathologic slides
Description: HE-stained whole slide images were used for the validation of the PSN-AI model.
Study: NCT05460455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Description: HB0034 and Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Description: HB0034 and Placebo
Study: NCT05793008

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) analysis
Description: 18F-FDG-PET/CT imaging will be performed 3 months after the acute event at the Department of Nuclear Medicine of Fondazione Policlinico Universitario A. Gemelli IRCCS using an integrated scanner. Intravenous 18F-FDG (370 MBq) will be given following an overnight fast. Three-dimensional PET imaging will be performed after 1 h of quiet waiting. A non-gated, non-contrast CT will be acquired for attenuation correction. Brain structures analyzed will include the neocortex, limbic system (insula, amygdala, cingulate cortex, and hippocampus), reticular formation, brainstem, and spinal cord.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: At the time of coronary angiography for patients with primary or secondary TTS and within the first 48 hours for patients with sepsis or septic shock, arterial blood samples will be collected in 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes. Furthermore, a hair sample of 6 cm will be collected for hair cortisol assay.~For patients with primary or secondary TTS blood samples will be collected by venipuncture with 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes also at 3 months follow-up.~Blood samples will be immediately centrifuged to obtain whole blood, serum, and plasma samples, and then aliquoted into Eppendorf-type tubes. All samples will then be stored at -80°C until the analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: At the time of coronary angiography for patients with primary or secondary TTS and within the first 48 hours for patients with sepsis or septic shock, arterial blood samples will be collected in 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes. Furthermore, a hair sample of 6 cm will be collected for hair cortisol assay.~For patients with primary or secondary TTS blood samples will be collected by venipuncture with 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes also at 3 months follow-up.~Blood samples will be immediately centrifuged to obtain whole blood, serum, and plasma samples, and then aliquoted into Eppendorf-type tubes. All samples will then be stored at -80°C until the analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow up visit
Description: Participation in this study requires for patients with primary vs secondary TTS, a follow-up visit at 3 months (90 +/- 5 gg) after enrollment to assess a Positron Emission Tomography (PET) analysis, and during the same visit, venous blood sampling as described above will be further performed.
Study: NCT05460455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Description: HB0034 and Placebo
Study: NCT05616000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine, folic acid
Description: Acetyl-l-carnitine 2gm once a day\& folic acid will be given to 43 primary infertile men
Study: NCT06235567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical prednisolone acetate 1% (PredForte) eye drops
Description: The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
Study: NCT06000124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
Study: NCT06341660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.